Published in Biochem Pharmacol on February 01, 1969
Clonidine distribution in the rat: temporal relationship between tissue levels and blood pressure response. Br J Pharmacol (1980) 0.82
Comparison of the actions of centrally and peripherally administered clonidine and guanfacine in the rabbit: investigation of the differences. Br J Pharmacol (1982) 0.77
Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A (1971) 2.00
Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci (1995) 1.91
Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem (1968) 1.80
Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther (1979) 1.65
Electrophysiological indicator of awakening from coma. Lancet (1993) 1.61
Clinical and biochemical comparison of clorazepate and diazepam. Psychol Med (1974) 1.46
Influence of posture on plasma nitroglycerin. Br J Clin Pharmacol (1985) 1.45
Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med (1971) 1.43
A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med (1992) 1.42
Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch Gen Psychiatry (1970) 1.42
Ice: a new dosage form of an old drug. Science (1990) 1.41
Uptake of disodium cromoglycate in obstructive airways disease. Clin Allergy (1973) 1.38
Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med (1994) 1.38
Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther (1973) 1.36
Plasma protein binding of chlorpromazine. J Pharm Pharmacol (1970) 1.30
Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients. Life Sci (1968) 1.29
The physiological disposition of chlorpromazine in the rat and dog. Proc Soc Exp Biol Med (1970) 1.28
Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine. Clin Pharmacol Ther (1970) 1.28
Plasma concentrations in the monkey (Macaca mulatta) of six related benzodiazepines after intraperitoneal injection [proceedings]. Br J Pharmacol (1976) 1.24
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol (1994) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther (1995) 1.21
Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol (1996) 1.18
Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther (1990) 1.16
Treatment of lactic acidosis with dichloroacetate. N Engl J Med (1983) 1.11
Rates of alkaline hydrolysis and muscarinic activity of some aminoacetates and their quaternary ammonium analogs. J Med Chem (1972) 1.03
Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response. J Pharmacol Exp Ther (1997) 1.02
Plasma-trifluoperazine concentrations during high dose therapy. Lancet (1981) 1.01
Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther (1985) 1.00
Preparation and stability of indomethacin solutions. Can J Physiol Pharmacol (1982) 1.00
Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci (1972) 0.99
Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol (1971) 0.99
Chlorpromazine plasma levels and effects. Arch Gen Psychiatry (1970) 0.93
Nitroglycerin levels after administration via transdermal therapeutic system or nitroglycerin ointment. Lancet (1984) 0.92
Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration. Am J Vet Res (1984) 0.92
Disposition of glutethimide in man. Clin Pharmacol Ther (1971) 0.92
The influence of pH on the muscarinic action of oxotremorine, arecoline, pilocarpine, and their quaternary ammonium analogs. Mol Pharmacol (1966) 0.91
Effect of dose and ointment application technique on nitroglycerin plasma concentrations. Pharmacotherapy (1983) 0.91
Event-related potentials--neurophysiological tools for predicting emergence and early outcome from traumatic coma. Intensive Care Med (1996) 0.91
Interaction of glutethimide and phenobarbitone with ethanol in man. J Pharm Pharmacol (1972) 0.91
Methods for study of fluphenazine kinetics in man. J Pharm Pharmacol (1976) 0.91
Letter: A note on the analysis of disodium cromoglycate (Intal) in human urine. J Pharm Pharmacol (1973) 0.90
Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3. Biochemistry (2001) 0.89
Destruction of chlorpromazine during absorption by rat intestine in vitro. Br J Pharmacol (1970) 0.89
Effects of phenylbutazone on liver microsomal demethylase. Biochem Pharmacol (1970) 0.89
Acute tolerance to a sedative in man. Br J Pharmacol (1970) 0.88
Double-blind trial of fluphenazine decanoate. Lancet (1972) 0.88
Pharmacokinetics of closely related benzodiazepines. Br J Clin Pharmacol (1979) 0.88
Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats. Fundam Appl Toxicol (1990) 0.88
Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues. J Pharm Pharmacol (1970) 0.87
Proceedings: Clinical pharmacology of chlorpromazine. Br J Pharmacol (1972) 0.87
Behavioural and pharmacokinetic studies in the monkey (Macaca mulatta) with diazepam, nordiazepam and related 1,4-benzodiazepines. Br J Pharmacol (1977) 0.87
Plasma-fluphenazine concentrations after injection of long-acting esters. Lancet (1978) 0.86
Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol (1992) 0.86
On mechanisms of norepinephrine release by amphetamine and tyramine and tolerance to their effects. Adv Biochem Psychopharmacol (1969) 0.86
Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection. J Pharm Pharmacol (1986) 0.85
Folate and pterin metabolism by cancer cells in culture. Cancer Res (1978) 0.85
Clinical effects and metabolism of diazepam in patients with chronic liver disease. Clin Sci (Lond) (1982) 0.84
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol (1997) 0.84
Improved EMIT analysis for lidocaine. Clin Chem (1985) 0.84
Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology (1990) 0.84
Drug metabolism in man: past, present, and future. Ann N Y Acad Sci (1971) 0.84
The interaction of the beta-haloethyl benzylamines, xylamine, and DSP-4 with catecholaminergic neurons. Annu Rev Pharmacol Toxicol (1990) 0.83
Long-acting phenothiazines in schizophrenia. Br Med J (1971) 0.83
The form and distribution of auditory evoked potentials and CNVs when stimuli and responses are lateralized. Prog Brain Res (1980) 0.83
Concentration-effect relationships with major and minor tranquilizers. Clin Pharmacol Ther (1974) 0.83
l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J Pharmacol Exp Ther (1999) 0.83
Bratton-Marshall and liquid-chromatographic methods compared for determination of sulfamethazine acetylator status. Clin Chem (1981) 0.83
Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry (1978) 0.83
The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav (1989) 0.82
Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem Res Toxicol (1991) 0.82
Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol (1989) 0.82
Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine. J Pharmacol Exp Ther (1996) 0.82
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol (1979) 0.82
Interaction of xylamine with peripheral sympathetic neurons. Life Sci (1985) 0.82
Quantitative electroencephalographic evaluation of non-fatal and fatal traumatic coma. Electroencephalogr Clin Neurophysiol (1998) 0.82
The pharmacologic effects of ST-155 (Catapres) and related imidazolines in the rat. Pharmacology (1969) 0.81
Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry (1980) 0.81
Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol (1994) 0.81
Analysis of plasma trifluoperazine by gas chromatography and selected ion monitoring. J Chromatogr (1982) 0.81
Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit (1987) 0.80
Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug. J Pharm Pharmacol (1969) 0.80
Spectral and inhibitory interactions of (+/-)-3,4-methylenedioxyamphetamine (MDA) and (+/-)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. Life Sci (1986) 0.80
Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine. Dis Nerv Syst (1973) 0.80
Modulation of neostriatal acetylcholine in the rat by dopamine and 5-hydroxytryptamine afferents. Life Sci (1976) 0.80
Microsomal N-hydroxylation of phenylalkylamines. Identification of N-hydroxylated phenylalkylamines as their trimethylsilyl derivatives by GC-Ms. Acta Pharm Suec (1973) 0.80
Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol Pharm Bull (2001) 0.80
Effects of alpha-carbon substituents on the N-demethylation of N-methyl-2-phenethylamines by rat liver microsomes. Drug Metab Dispos (1983) 0.79
Compartmental analysis of tyramine-induced norepinephrine depletion. Pharmacology (1981) 0.79
Drug distribution and effect. J R Coll Physicians Lond (1970) 0.79
In vivo folate kinetics during chronic supplementation of human subjects with deuterium-labeled folic acid. J Nutr (1992) 0.79
Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects. J Med Chem (1991) 0.79
The effects of xylamine, a nitrogen mustard on [3H]norepinephrine accumulation in rabbit aorta. J Pharmacol Exp Ther (1980) 0.79
Application of quantitative GC-mass spectrometry to study of pharmacokinetics of amphetamine and phentermine. J Pharm Sci (1973) 0.79
Xylamine, an irreversible inhibitor of norepinephrine uptake, is transported by this same uptake mechanism in cultured rat superior cervical ganglia. J Pharmacol Exp Ther (1983) 0.79
Inhibition of norepinephrine accumulation by amphetamine derivatives: studies with rat brain and rabbit aorta. J Pharmacol Exp Ther (1977) 0.79
Accumulation of 4-hydroxyamphetamine by rat striatal homogenates. Biochem Pharmacol (1975) 0.79
Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine. Biopharm Drug Dispos (1990) 0.78
Inhibition of uptake of catecholamines by benzylamine derivatives. J Med Chem (1979) 0.78
Urinary excretion of chlorpromazine metabolites following single doses and in steady-state conditions. Res Commun Chem Pathol Pharmacol (1971) 0.78